Gilead bets $66M upfront for Tentarix’s protein therapeutics in inflammation, cancer

Gilead will pony up $66 million in an upfront payment and equity investment to collaborate with Tentarix Biotherapeutics on biologics for inflammatory diseases and oncology, the companies said Tuesday morning.

San Diego-based Tentarix could receive up to another $240 million if Gilead elects to acquire three of the biotech’s subsidiaries…
Click here to view original post